J.B. Chemicals & Pharmaceuticals growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+5.9%+12.5%+10.6%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+7.3%+15.0%+28.9%
+7.5%+13.5%+30.5%
+7.6%+19.4%+34.8%
+6.4%+19.0%−32.7%
+16.3%+7.0%+12.4%
+21.1%+17.4%+17.9%
−22.0%+12.7%+28.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

JBCHEPHARM

J.B. Chemicals & Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersTORNTPHARMALKEMIPCALABSAILIFENHNEULANDLABACUTAASNATCOPHARM
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Revenue Growth—+10.6+12.5+5.9
EBITDA Growth—+28.9+15.0+7.3
EBIT Growth—+30.5+13.5+7.5
Net Income Growth—+34.8+19.4+7.6
EPS Growth—-32.7+19.0+6.4
Total Assets Growth—+12.4+7.0+16.3
Total Equity Growth—+17.9+17.4+21.1
Cash from Operations Growth—+28.0+12.7-22.0
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.